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Background: Spurred by success in several foci, onchocerciasis control policy in Africa has shifted from morbidity
control to elimination of infection. Clinical trials have demonstrated that moxidectin is substantially more efficacious
than ivermectin in effecting sustained reductions in skin microfilarial load and, therefore, may accelerate progress
towards elimination. We compare the potential cost-effectiveness of annual moxidectin with annual and biannual
ivermectin treatment.
Methods: Data from the first clinical study of moxidectin were used to parameterise the onchocerciasis transmission
model EPIONCHO to investigate, for different epidemiological and programmatic scenarios in African savannah
settings, the number of years and in-country costs necessary to reach the operational thresholds for cessation of
treatment, comparing annual and biannual ivermectin with annual moxidectin treatment.
Results: Annual moxidectin and biannual ivermectin treatment would achieve similar reductions in programme
duration relative to annual ivermectin treatment. Unlike biannual ivermectin treatment, annual moxidectin treatment
would not incur a considerable increase in programmatic costs and, therefore, would generate sizeable in-country cost
savings (assuming the drug is donated). Furthermore, the impact of moxidectin, unlike ivermectin, was not substantively
influenced by the timing of treatment relative to seasonal patterns of transmission.
Conclusions: Moxidectin is a promising new drug for the control and elimination of onchocerciasis. It has high
programmatic value particularly when resource limitation prevents a biannual treatment strategy, or optimal timing of
treatment relative to peak transmission season is not feasible.
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The primary goal of onchocerciasis control in Africa
has recently shifted from morbidity prevention to
elimination of the infection where possible by 2025 [1],
including elimination of onchocerciasis in selected
African countries by 2020 [2]. Currently, the predominant* Correspondence: hugo.turner06@imperial.ac.uk
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unless otherwise stated.control strategy in Africa is preventative chemotherapy by
annual community-directed treatment with ivermectin
(aCDTI). Merck & Co committed to donate ivermectin
for as long as needed to eliminate the public health bur-
den of onchocerciasis [3].
The global health community recognises that the res-
ervoir of Onchocerca volvulus will not be eliminated in
all endemic foci in Africa with aCDTI alone, and that
new tools and strategies are needed [2]. In the 13
endemic foci in Latin America (population at risk
approximately 0.56 million), biannual ivermectin mass
treatment (complemented in certain hyperendemic
areas with more frequent administration) has, or is
likely to have, interrupted transmission in 11 foci [4,5].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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achieving elimination in Africa, which has a population
at risk of onchocerciasis of approximately 115 million
people [6]. In some foci in Senegal 17 years of bCDTI
interrupted onchocerciasis transmission [7,8]. Ghana
and Uganda currently implement bCDTI in selected
foci [9,10], and bCDTI was also used in several of the
Special Intervention Zones after the closure of the
former Onchocerciasis Control Programme in West
Africa (OCP) [11].
A previous modelling study [12] indicated that although
bCDTI yields only small additional health benefits rela-
tive to aCDTI, it substantially reduces the number of
years required to reach the provisional operational
thresholds for treatment interruption followed by sur-
veillance (pOTTIS) [13]. This reduction is most pro-
nounced in areas with very high pre-control skin
microfilarial prevalence, where model projections sug-
gest that elimination would not be possible with over
50 years of aCDTI. Furthermore, bCDTI would reduce
the difference in years to reach the pOTTIS among
areas with very different pre-control endemicities [12].
This is noteworthy since CDTI should only be stopped
when there is sufficiently low risk of re-introduction of
the parasite from neighbouring areas.
A subsequent and recent modelling study has also
found that increasing the treatment frequency of iver-
mectin to twice per year notably reduces the programme
duration (also by about 35% in mesoendemic and hyper-
endemic settings) [14]. Though these reductions were
found to be highly dependent on the level of maintained
coverage, and could be completely nullified if coverage
were to fall [14].
In Ghana, bCDTI has increased programmatic costs
by 50-60% per year relative to aCDTI [15]. Conse-
quently, even with a marked reduction in the number
of years to reach the pOTTIS, model projections indi-
cate that bCDTI in many areas will have a higher total
cost than aCDTI [12]. Furthermore, bCDTI may not
always be feasible, particularly where resources are
scarce or access to communities is only possible during
dry seasons.
Moxidectin is a highly efficacious veterinary anthel-
mintic [16] and a potential alternative to ivermectin for
preventive chemotherapy and elimination of human
onchocerciasis. In a Phase II clinical trial, moxidectin re-
duced skin microfilarial loads to statistically significantly
lower levels and for substantially longer than ivermectin
[17]. The effect through 1 year after treatment supports
the hypothesis that annual community-directed treat-
ment with moxidectin (aCDTM) has an effect on trans-
mission comparable to that of bCDTI.
We tested this hypothesis by modelling aCDTI, bCDTI
and aCDTM strategies, assessing the time and cost toreach the pOTTIS under a variety of epidemiological
and programmatic conditions. These included, for the
first time, the effect of the timing of treatment relative
to seasonal transmission patterns. In some foci, the
breeding sites of the simuliid vectors dry up and biting
rates dwindle to zero, potentially decreasing the effect-
iveness of ivermectin treatment if it is not timed to en-
sure minimal skin microfilarial levels when biting rates
are highest [7,8].
Methods
Onchocerciasis transmission model
The modelling was undertaken using EPIONCHO, a host
sex- and age-structured deterministic onchocerciasis trans-
mission model [18,19], parameterised for African savannah
settings [18]. The underlying demography is that of
northern Cameroon, assuming a stationary age distribu-
tion and a stable (closed) population [18].
For all modelling not aimed at assessing the impact of
treatment timing relative to transmission season, peren-
nial transmission (all year round) was assumed (Table 1).
To model seasonal peaks in transmission, the biting rate
of blackfly (Simulium damnosum) vectors was allowed
to vary throughout the year (Additional file 1: Table S1
and Additional file 1: Figure S1).
Drug effects
EPIONCHO incorporates the temporal dynamics of the
microfilaricidal and embryostatic (temporary sterilisa-
tion of female worm) effects of ivermectin, based on
previous modelling of data from clinical and commu-
nity trials of ivermectin (Figure 1A) [20]. The temporal
dynamics of skin microfilarial loads from the ivermec-
tin treatment arm in the Phase II moxidectin study
were within the range observed in [20]. Moxidectin
treatment was assumed to exert the same types of
effects on the parasite as ivermectin. Therefore, moxi-
dectin’s effects were parameterised by fitting the func-
tions in [20] to the percentage reduction in skin
microfilarial densities from pre-treatment, measured
8 days, 1, 2, 3, 6, 12 and 18 months after a single dose
of 8 mg moxidectin (91–186 μg/kg or 0.14-0.29 μmol/kg
for the weight range included) in 38 adult hosts [17]
(Figure 1B, Additional file 1: Table S2).
Given the uncertain, and somewhat controversial
[19,21] cumulative effect of repeated ivermectin expos-
ure of adult worms on their rate of microfilarial produc-
tion (anti-macrofilarial action), modelling was conducted
assuming 7% cumulative reduction per standard dose of
ivermectin ( 150 μg/kg or 6, 9 or 12 mg, 0.16-0.23 μmol/kg
for the weight range in the 8 mg moxidectin arm of the
Phase II study) as well as extreme values of 1% and 30%
[19,21] (Table 1). No data exist on the effect of multiple
doses of moxidectin, so we assumed the same cumulative
Table 1 Summary of factors whose impact was modelled on the duration and cost of reaching the pOTTIS
Parameters Values
Seasonality of transmission (see Supporting information
(Additional file 1: Text S.1, and Additional file 1: Figure S1))
Perennial transmission: annual biting rate (ABR) is constant throughout
the year (i.e. no seasonal changes)
Seasonal transmission scenario 1: transmission occurs during a rainy
season typically lasting approximately five months each year; based
on foci in Senegal and Mali [7,8] were elimination has been reported
Seasonal transmission scenario 2: a longer period of transmission, still
peaking in the rainy season but not ceasing completely in the dry
season; motivated by the entomological observations in [40]
The proportion of the total population receiving ivermectin or
moxidectin at each treatment round, referred to as therapeutic
coverage
60% and 80%
The proportion of the eligible population who never receive
treatment, referred to as the proportion of systematic
non-compliers
0.1%, 2% and 5%
The discount rate applied to the costs [23] 0%, 3% and 6%
The per treatment round cost of aCDTM relative to aCDTI 100% (i.e. the same) and 110%
The per dose (cumulative) reduction in microfilarial production of
female adult worms, referred to as anti-macrofilarial action of
ivermectin
1%, 7% and 30%
Provisional Operational Thresholds for Transmission Interruption
followed by Surveillance (pOTTIS)
0.9%, 1.4% and 1.9% microfilarial prevalence (i.e. 1.4% ± 0.5%)
aCDTM: annual community-directed treatment with moxidectin; aCDTI: annual community-directed treatment with ivermectin; pOTTIS: provisional operational
thresholds for treatment interruption followed by surveillance.
Turner et al. Parasites & Vectors  (2015) 8:167 Page 3 of 12anti-macrofilarial effect size as for ivermectin. (Note that
the embryostatic effect is assumed to be temporary,
whereas the anti-macrofilarial action is assumed to be cu-
mulative.) It was also assumed that, like ivermectin, indi-
viduals aged > = 5 years would be eligible for moxidectin
treatment.Figure 1 The dynamic effect of a single dose of ivermectin (A) and m
from skin microfilarial loads (the mean of four microfilarial counts [17]) colle
(B) the 38 treated participants (who took moxidectin) as part of the Phase
[17]. The effect of a single dose of ivermectin previously fitted to microfilar
solid blue line in (A) (note that the microfilarial dynamics induced by ivermec
ous parameterization). The dynamical effect precipitated by moxidectin was fi
the same approach as in [20] (described in the Supporting information (Addit
show the 95% confidence intervals which in some circumstances were narrowOperational thresholds for treatment interruption
followed by surveillance (pOTTIS)
The African Programme for Onchocerciasis Control (APOC)
conceptual and operational framework for elimination
[13] proposed provisional operational thresholds for
treatment interruption followed by surveillance (pOTTIS).oxidectin (B) on skin microfilarial load. The data points are derived
cted from (A) the 45 control participants (who took ivermectin) and
II clinical safety trial of moxidectin for the treatment of onchocerciasis
ial load data collated as part of a meta-analysis [20] is shown as the
tin are not re-estimated here and hence provide a validation of the previ-
tted to the trial data on microfilarial loads from treated participants using
ional file 1: Text S.2)) and is shown as the solid red line in (B). Error bars
er that the plotted data point and so are not discernible.
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human population (skin snip-based microfilarial preva-
lence of <5% in all surveyed villages and <1% in 90%
of surveyed villages), and fly infectivity (<0.5 infective
larvae per 1,000 blackflies). The pOTTIS are not
necessarily equivalent to a transmission breakpoint, a
hypothetical parasite density below which the popula-
tion would be unable to maintain itself [22].
As in our previous analysis of bCDTI [12], we
assumed that the pOTTIS were reached when the
modelled microfilarial prevalence (all ages), measured
just before the next treatment round, fell below 1.4%,
the weighted average of the pOTTIS prevalence thresh-
olds. We used the microfilarial prevalence thresholds
because in our simulations the entomological threshold
was always reached sooner [12], making the former
more conservative. Since the pOTTIS are provisional
[13], we also modelled pOTTIS of 0.9% and 1.9% micro-
filarial prevalence (Table 1).
In-country costs
The economic cost of aCDTI was set at US$41,534 per
100,000 individuals (overall target population) per year
(2012 prices). This increased by 60% for bCDTI. These costs
were estimated from data collected in Ghana [15] and are
those incurred by the Ministry of Health, non-government
organization (NGO) partners and volunteer community
distributors. (The health care providers’ perspective was
chosen because the costs to the local community for acces-
sing treatment should be negligible.) The economic value
of donated ivermectin was not included [15].
The cost of aCDTM was assumed to be either identi-
cal to that of aCDTI or 10% higher to account for poten-
tial extra costs of social mobilization and training to
distribute a new drug. It was assumed that moxidectin
would, like ivermectin, be donated to endemic countries.
Following WHO guidelines [23], a discount rate of 3%
was applied to the costs. Discounting deflates costs in-
curred in the future to reflect that society prefers to
delay costs rather than incur them in the present.
Scenarios modelled
EPIONCHO was used to project the number of years of
treatment required to reach the pOTTIS (programme
duration) and the associated in-country costs with
aCDTI, bCDTI and aCDTM over a 50-year time horizon
for a range of initial endemicity levels (40%, mesoendemic;
60%, hyperendemic; 80%, highly hyperendemic pre-control
microfilarial prevalence; Additional file 1: Table S3). For
each endemicity level, programme duration and cost were
subjected to a sensitivity analysis (Table 1). In addition, dif-
ferent timing of aCDTI and aCDTM treatment relative to
peak transmission was modelled for two seasonal transmis-
sion scenarios (see Supporting information).Results
In the Phase II clinical trial, a single dose of 8 mg moxi-
dectin reduced pre-treatment skin microfilarial levels by
98%-100% from 8 to 365 days after treatment (Figure 1B,
[17]). This higher and more prolonged efficacy com-
pared to ivermectin (Figure 1A) resulted in shorter sim-
ulated programme durations for aCDTM than aCDTI.
This was found to apply both when aCDTM is used
from the outset (Table 2, Figure 2) and when a switch
from aCDTI to aCDTM is made during ongoing control
activities (Figure 3, Additional file 1: Table S4). The
programme durations with aCDTM were comparable to
those with bCDTI. For both bCDTI and aCDTM, the
reductions in programme duration relative to aCDTI
increased with increasing baseline prevalence of infection
(Figure 2, Figure 3, Additional file 1: Table S4), i.e. the
benefits of more effective strategies accrued dispropor-
tionately with increasing initial endemicity. Like bCDTI
[12], aCDTM reduced the difference in programme
duration between areas with different pre-control ende-
micities relative to aCDTI (Figure 2, Figure 3, Additional
file 1: Table S4). The decrease and increase in programme
duration when increasing or decreasing, respectively,
the pOTTIS, from 1.4% to 1.9% or 0.9% average skin
microfilarial prevalence were similar for all three strat-
egies (as indicated by the error bars in Figures 2 and 3).
Impact of therapeutic coverage and compliance
Decreasing therapeutic coverage from 80% to 60% and/or
increasing the percentage of systematic non-compliers
(those who never take treatment) from 0.1% to 5% mark-
edly increased programme duration for all three strategies
(Figure 4, Table 3). The simulated programme durations
with aCDTM were notably less sensitive to variation in
therapeutic coverage than those with aCDTI. However,
similar to aCDTI and bCDTI [12], aCDTM was highly
sensitive to assumed proportions of systematic non-
compliance (Figure 4, Table 3).
Impact of anti-macrofilarial action
The data from the single dose Phase II trial do not permit
drawing conclusions on the relative effects of moxidectin
and ivermectin on adult worm viability or permanent
reproductive capacity [17]. There are no data on the
potential cumulative anti-macrofilarial activity of repeated
annual doses of moxidectin, which is also uncertain for
ivermectin [19,21]. The projected programme durations
with aCDTM were substantially less sensitive to the as-
sumed anti-macrofilarial action (the per dose cumulative
reduction in microfilarial production by female adult
worms) than aCDTI or bCDTI within the 1% to 30%
range investigated. The difference in programme durations
between aCDTM and CDTI (aCDTI or bCDTI) was high-
est when assuming a very low, 1% anti-macrofilarial action
Table 2 Sensitivity of the duration (time to achieve pOTTIS) and relative total cost of annual ivermectin (aCDTI), biannual
ivermectin (bCDTI) and annual moxidectin (aCDTM) treatment programmes to the magnitude of the assumed
anti-macrofilarial action of ivermectin and moxidectin
Baseline endemicity level
(microfilarial prevalence)
1% cumulative reduction in
microfilarial production by
female adult worms per dose
7% cumulative reduction in
microfilarial production by
female adult worms per dose
30% cumulative reduction in
microfilarial production by
female adult worms per dose
Projected duration, in years,
of treatment programme
(relative cost, in percent)
Projected duration, in years,
of treatment programme
(relative cost, in percent)
Projected duration, in years,
of treatment programme
(relative cost, in percent)
aCDTI bCDTI (ǂ) aCDTM (ǂ,†) aCDTI bCDTI (ǂ) aCDTM (ǂ,†) aCDTI bCDTI (ǂ) aCDTM (ǂ,†)
Mesoendemic (40%) 21 14 (118%) 12 (65%, 55%) 17 11 (113%) 11 (71%, 63%) 12 9 (126%) 10 (86%, 68%)
Hyperendemic (60%) 33 20 (115%) 18 (67%, 58%) 25 16 (116%) 17 (76%, 66%) 17 14 (138%) 15 (91%, 66%)
Highly-hyperendemic (80%) NA 38 (140%) 30 (76%, 54%) NA 26 (112%) 26 (70%, 63%) 38 22 (114%) 23 (74%, 65%)
ǂPercentage cost relative to aCDTI. †Percentage cost relative to bCDTI. NA: Operational thresholds for treatment interruption not attained within the 50-year time
horizon (and percentage of costs calculated based on costs of 50 years of aCDTI). The analysis was performed with a 50-year time horizon, therapeutic coverage
of 80%, 0.1% systematic non-compliers, perennial transmission, and pOTTIS of <1.4% microfilarial prevalence. Costs do not include value of the (donated) drugs. A
summary of the pre-control conditions is provided in Additional file 1: Table S3.
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sumed anti-macrofilarial action to 30%, markedly reduced
the projected programme durations with aCDTI and, to a
lesser extent bCDTI, while those with aCDTM were
hardly affected. Under all assumptions about the anti-
macrofilarial action, the projected programme durationFigure 2 Comparison of annual and biannual community-directed
treatment with ivermectin (aCDTI, bCDTI) versus annual
community-directed treatment with moxidectin (aCDTM) in
areas where control has not been previously implemented.
The green, blue and red bars correspond to a pre-control endemicity
level of 40%, 60%, and 80% microfilarial prevalence, respectively. The
aCDTI, bCDTI and aCDTM strategies are indicated by solid, dashed and
dotted bars respectively. Error bars represent the results of varying the
provisional operational thresholds for treatment interruption followed by
surveillance (pOTTIS) by adding or subtracting 0.5% (i.e. 0.9% or 1.9%
microfilarial prevalence). Results shown assume a therapeutic coverage
of 80%; a proportion of systematic non-compliers of 0.1%; perennial
transmission, and a 7% per dose (cumulative) reduction in microfilarial
production of female adult worms. A discount rate of 3% was
applied to the costs. *pOTTIS (1.4% microfilarial prevalence) not
attained within the 50-year time horizon and percentage of costs
calculated based on costs of 50 years of aCDTI. † Costs do not include
value of the (donated) drugs.with aCDTM was always clearly shorter than that with
aCDTI. With a 30% (and at times 7%) anti-macrofilarial
action, bCDTI programmes were one year shorter than
aCDTM programmes, but at a notably higher total cost
(Table 2, Additional file 1: Table S4).Impact of timing of aCDTI and aCDTM in areas with
seasonal transmission
The timing of aCDTI relative to seasonal transmission
peaks had a striking effect on programme duration
(Figure 5). The higher the initial endemicity and the
more extreme the pattern of seasonal transmission
(Figure 5 and Additional file 1: Figure S1), the greater
the importance of CDTI timing to ensure maximum
reduction in skin microfilarial loads during the peak
transmission period. In contrast, timing of aCDTM had
little effect on programme duration because of the
sustained, year-long suppression of microfilaridermia
(Figure 1B).In-country costs
Provided moxidectin is donated to endemic countries,
the shorter programme durations with aCDTM would
lead to substantial in-country cost savings compared to
aCDTI, even when aCDTM is assumed to be 10% more
costly to deliver than aCDTI (Additional file 1: Table S5).
Given that bCDTI costs around 60% more per year than
aCDTI [15], the similar programme durations of bCDTI
and aCDTM make aCDTM even more cost effective. Cost
savings of aCDTM were considerable compared with
bCDTI even under scenarios of maximum bCDTI
efficacy (assuming a 30% per dose (cumulative) anti-
macrofilarial action). Cost savings with aCDTM decreased
with increasing discount rates, but costs of aCDTM were
at least 19% lower than those of aCDTI and up to 39%
Figure 3 Impact of switching to biannual community-directed treatment with ivermectin (bCDTI) or annual community-directed
treatment with moxidectin (aCDTM) at different stages of an ongoing annual CDTI (aCDTI) programme. The green, blue and red bars
correspond to a pre-control endemicity level of 40%, 60%, and 80% microfilarial prevalence, respectively. The aCDTI, bCDTI and aCDTM strategies
are indicated by solid, dashed and dotted bars, respectively. Error bars represent the results of varying the provisional operational thresholds for
treatment interruption followed by surveillance (pOTTIS) by ± 0.5%. The number of additional years of treatment and the ratio of additional costs
are considered from the point of switching to bCDTI or aCDTM (and not from the start of control). Modelling assumptions are as in the legend of
Figure 2. *pOTTIS (1.4% microfilarial prevalence) not attained within the 50-year time horizon and percentage of costs calculated based on costs
of 50 years of aCDTI. † Costs do not include value of the (donated) drugs.
Turner et al. Parasites & Vectors  (2015) 8:167 Page 6 of 12lower than those of bCDTI even with a discount rate as
high as 6% [23] (Additional file 1: Table S6).
Discussion
Programme duration and cost savings
Model outputs indicate that annual moxidectin distribution
(aCDTM) is similarly effective for reaching the provisionalthresholds for interrupting treatment (pOTTIS) as increas-
ing the frequency of ivermectin distribution from once
(aCDTI) to twice per year (bCDTI). This is attributed to
the fact that moxidectin reduces skin microfilarial loads
faster, more pronouncedly, and for longer than ivermectin
(Figure 1), effectively halting transmission between con-
secutive yearly treatments, akin to a drug that sterilizes
Figure 4 The effect of coverage and non-compliance on programme duration under strategies of annual and biannual community-directed
treatment with ivermectin (aCDTI, bCDTI) and annual community-directed treatment with moxidectin (aCDTM). Black bars represent the
increment in programme duration caused by a decrease in therapeutic coverage from 80% to 60% of the total population. The green, blue and red
bars correspond to a pre-control endemicity level of 40%, 60%, and 80% microfilarial prevalence, respectively. aCDTI, bCDTI and aCDTM are indicated
by solid, dashed and dotted bars, respectively. Modelling assumptions are as in the legend of Figure 2. *Provisional operational threshold for treatment
interruption followed by surveillance (pOTTIS <1.4% microfilarial prevalence) not attained within the 50-year time horizon.
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explains why simulated programme durations with
aCDTM were not as sensitive as those with aCDTI or
bCDTI to the assumed magnitude of anti-macrofilarial ac-
tion (the per dose reduction in microfilarial production offemale adult worms) (Table 2, Additional file 1: Table S4).
The modelled anti-macrofilarial efficacy (1%, 7% or 30%
per dose cumulative reduction in microfilarial production)
with bCDTI accumulates twice as fast as with aCDTI or
aCDTM. Despite this, even at an assumed 30% per dose
Table 3 Sensitivity of the duration (time to achieve pOTTIS) and relative total cost of annual ivermectin (aCDTI),
biannual ivermectin (bCDTI) and annual moxidectin (aCDTM) treatment programmes to the percentage of therapeutic
coverage and systematic non-compliance
Baseline endemicity level
(microfilarial prevalence)
Systematic
non-compliance
80% overall therapeutic coverage 60% overall therapeutic coverage
Projected duration, in years, of treatment
programme (relative cost, in percent)
Projected duration, in years, of treatment
programme (relative cost, in percent)
aCDTI bCDTI (ǂ) aCDTM (ǂ,†) aCDTI bCDTI (ǂ) aCDTM (ǂ,†)
Mesoendemic (40%) 0.1% 17 11 (113%) 11 (71%, 63%) 23 14 (108%) 15 (75%, 70%)
2.0% 18 13 (124%) 13 (78%, 63%) 24 15 (133%) 16 (75%, 66%)
5.0% 20 16 (136%) 16 (85%, 63%) 26 18 (124%) 19 (80%, 65%)
Hyperendemic (60%) 0.1% 25 16 (116%) 17 (76%, 66%) 37 19 (104%) 21 (70%, 67%)
2.0% 28 19 (123%) 20 (80%, 65%) 42 22 (108%) 24 (72%, 66%)
5.0% 32 24 (133%) 24 (83%, 63%) 49 28 (119%) 29 (76%, 64%)
Highly hyperendemic (80%) 0.1% NA 26 (112%) 26 (70%, 63%) NA 38 (140%) 46 (96%, 69%)
2.0% NA 40 (144%) 43 (80%, 65%) NA NA (160%) NA (100%, 63%)
5.0% NA NA (160%) NA (100%, 63%) NA NA (160%) NA (100%, 63%)
ǂPercentage cost relative to aCDTI. †Percentage cost relative to bCDTI. NA: Operational thresholds for treatment interruption not attained within the 50-year time
horizon (and percentage of costs calculated based on costs of 50 years of treatment). Modelling assumptions are as in the legend of Table 2.
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were only 1 year shorter than those employing aCDTM,
due to moxidectin’s pronounced effect on the repro-
ductive activity of the adult worms as modelled in order
to reproduce the very late and slow repopulation of skin
by microfilariae observed (Figure 1B).
When modelling perennial transmission, the model as-
sumes that bCDTI is given precisely every 6 months,
which does not always occur in practice. Delays in treat-
ment distribution will likely increase projected programme
durations as they would permit more transmission within
the year than the model assumed. This is particularly per-
tinent to bCDTI, as this would reduce its benefit relative
to aCDTI.
The aCDTM strategy was projected to generate marked
in-country cost savings (not including the cost of the drug,
assumed to be donated) compared to both aCDTI and
bCDTI under all assumptions on discount rates, even
when each aCDTM round was set to cost 10% more than
aCDTI. The largest cost savings occurred when aCDTM
was compared with bCDTI, which costs approximately
60% more per year than aCDTI [15].
Both bCDTI and aCDTM substantially reduced the het-
erogeneity in programme durations for areas with differ-
ent baseline endemicities. This has high programmatic
value because treatment should only be stopped when
there is little or no risk of parasite re-introduction from
neighbouring areas with continuing transmission. There-
fore, aCDTM could be a cheaper alternative to bCDTI
where progress towards elimination is lagging, reducing
the potential sources of infection in adjoining areas where
good progress has been made and thereby protecting the
economic and public health investments made.Coverage and compliance
While clinical trials of moxidectin have been conducted
to date only in participants aged ≥ 12 years [17] (Clini-
caltrials.gov/ct2/show/NCT00790998), a paediatric study
is part of the moxidectin clinical development plan [17].
Therefore, our modelling assumed that the age groups
eligible for ivermectin and moxidectin are identical
(≥5 years). Demonstration of the safety of moxidectin in
children 5 to 11 years will be crucial to ensure aCDTM
has the projected impact.
The longer lasting effects of moxidectin result in
aCDTM being substantially less sensitive than aCDTI to
the level of therapeutic coverage; aCDTM could thus
have particular value where coverage is relatively low
due to scarce resources or logistical difficulties; circum-
stances which would also impede bCDTI. All treatment
strategies were acutely and deleteriously affected by in-
creasing levels of systematic non-compliance, highlighting
the importance of reducing systematic non-compliance re-
gardless of the treatment strategy. Cost savings generated
by aCDTM could be partly invested in social mobilization
and other activities that increase compliance. Such initia-
tives will become more important in the advanced stages
of control as decreasing morbidity reduces individuals’
motivation to take treatment.
In highly hyperendemic areas with low coverage and/or
high levels of systematic non-compliance, neither aCDTM
nor bCDTI was sufficient to reach the pOTTIS within
meaningful timeframes. This highlights the importance of
alternative and/or complementary strategies including novel
macrofilaricidal therapies [24-27]—provided the necessary
compliance is achieved—and vector control [28] and, in the
longer term, a possible onchocerciasis vaccine [29].
Figure 5 The effect of the timing of treatment rounds relative to seasonal peaks in transmission by blackfly vectors on programme
duration under strategies of annual community-directed treatment with ivermectin (aCDTI) and annual community-directed treatment
with moxidectin (aCDTM). The time between treatment and the peak of transmission was varied. The x-axis represents the number of months
between treatment at time 0 and the peak of transmission. Scenario 1: transmission only takes place during a five month long rainy season. Scenario 2:
high levels of transmission during a five month long rainy season but continuing at a low level during the rest of the year (Table 1 and Additional file
1: Figure S1). The green, blue and red lines correspond to, respectively, a pre-control endemicity level of 40%, 60%, and 80% microfilarial prevalence.
The years are those needed to reach the pOTTIS (<1.4% microfilarial prevalence). The lines show the mean microfilarial load per mg of skin after
15 years of treatment in those aged ≥ 20 years. Solid and dashed lines indicate aCDTI and aCDTM respectively. Modelling assumptions are as in
the legend of Figure 2.
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The duration of aCDTI programmes was highly sensitive
to the timing of treatment relative to seasonal transmis-
sion patterns (Figure 5). This should be considered when
evaluating the best strategies for reaching elimination and
when smaller than expected reductions in prevalence of
infection are observed. Furthermore, in areas with highly
seasonal transmission, investment into implementing
bCDTI may not significantly reduce programme duration
and it could be more cost-effective to invest resources into
optimal timing and treatment coverage of aCDTI. This
analysis shows the need for further research into the
optimum timing of CDTI for all types of seasonal trans-
mission patterns in Africa. This is particularly relevant fordecisions on investing additional resources into bCDTI.
These investigations should include the impact and cost-
effectiveness of increasing overall treatment coverage
across the year by treating in the second yearly treatment
round individuals not treated in the first round.
The effectiveness of aCDTM was substantially less
sensitive to the transmission pattern and thus less
vulnerable to factors which affect the actual versus
planned timing of treatment (such as drug availability,
synergistic resource use in NTD programmes, access to
communities, and local community decisions). This is be-
cause of moxidectin’s high and prolonged efficacy, which
results in almost full, year-long suppression of microfilari-
dermia (Figure 1B). The aCDTM strategy would also be
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it difficult to guarantee regular and optimal timing of
aCDTI or bCDTI.
Limitations
Many of the methodological limitations of this analysis
have been previously discussed [12]; including the fact
that the model is currently parameterized for savannah
areas of Africa (and not forest settings). Furthermore,
the model does not account for any “spill over” infection
between neighbouring onchocerciasis foci and therefore
underestimates the value in reducing heterogeneity in
programme duration among areas with different baseline
endemicities and/or control programme performance.
The modelling of in-country costs assumes that moxi-
dectin would be donated to endemic countries and dis-
tributed with no or only a 10% increase in costs relative
to distribution of ivermectin. WHO has concluded an agree-
ment with the Australian not-for-profit organization Medi-
cines Development for Global Health (MDL, http://www.
medicinesdevelopment.com/) to transfer all moxidectin-
related data to MDL. MDL intends to register moxidec-
tin, initially for onchocerciasis, and ensure manufacturing.
The validity of this assumption is thus expected to become
clearer over the next couple of years.
The fit of our model to the skin microfilarial density
data from the Phase II trial (Figure 1) requires validation
against the dataset from the Phase III trial [30]. That
dataset is not as appropriate as the Phase II trial data set
for fitting the microfilarial temporal dynamics after moxi-
dectin treatment because it comprises fewer post-treatment
time points. However, it includes skin microfilarial densities
from around 25 times as many people as the Phase II trial.
The ongoing analysis of the Phase III study data [30]
suggests that the curve derived from the Phase II trial
(Figure 1) provides a good fit to the Phase III data on
skin microfilarial densities.
EPIONCHO is a deterministic model where all events
occur in a pre-specified way depending on the parameter
values and initial conditions of the model. It therefore
does not account for the influence of random events
and, in the context of elimination, the phenomenon of
stochastic fade-out [31] (chance elimination of the parasite
at low population densities). Consequently, EPIONCHO
cannot be used to investigate formally the probability of
reaching elimination. Furthermore, it is parameterized for
the savannah species of the S. damnosum s.l. vector com-
plex (S. damnosum s. str. and S. sirbanum) [18,32], and
the influence of different combinations of vectors on the
impact of control requires further investigation. Finally, it
is important to consider that most models of helminth
transmission dynamics (including EPIONCHO) are parame-
terized with data collected before commencement of
control and formal validation against longitudinal datafrom ongoing interventions is scant. It is possible that the re-
lationships between infection and transmission could be in-
fluenced by the treatment [33]. Therefore, any model-derived
predictions of the long-term impact of treatment have a de-
gree of uncertainty.
Other considerations relating to the use of moxidectin
Moxidectin exerts a more potent initial microfilaricidal
effect than ivermectin [17]. Consequently, it is likely that
moxidectin, like ivermectin, will be contraindicated in
patients with heavy Loa loa co-infections because of the
risk of severe and/or serious adverse events associated
with rapid microfilaricidal activity against L. loa micro-
filariae [24,34]. This highlights the need for drugs with-
out microfilaricidal activity [24-26] and complementary
vector control strategies for L. loa co-endemic areas.
Alternatively, moxidectin could be considered in these
areas within the ‘test for loiasis and do not treat’ strat-
egy now being explored for ivermectin (possibly also
including a test for onchocerciasis and alternative treat-
ment), to identify and exclude individuals at risk of
severe and/serious adverse reactions to treatment. In
that case, the applicability of risk thresholds determined
for ivermectin needs to be carefully considered.
The pOTTIS are provisional operational thresholds for
stopping treatment followed by surveillance based on
the experience with vector control in the OCP, aCDTI
and bCDTI in Mali and Senegal and projections from
(other) transmission models [7,8,13]. They include the
residual level of patent infection across the whole age
range assessed via skin microfilarial prevalence. The
longer lasting effect of moxidectin on microfilarial pro-
duction by female worms, if shown not to be associated
with an irreversible effect after multiple doses, needs to
be considered in the choice of time for the assessment
post treatment. This is not the case if antibody prevalence
in 1–5 year olds, born after the presumed interruption of
transmission, is used as one of the criteria for stopping
treatment as in the 2001 WHO guidelines for certification
of onchocerciasis elimination, developed in view of elimin-
ation in the Americas [35] and currently under review.
Furthermore, it is important to reiterate that the
current pOTTIS are provisional and not necessarily
equivalent to the true transmission breakpoint for elim-
ination in all settings. In particular, in areas with very
high pre-control endemicity levels, with high vector bit-
ing rates, the breakpoint may be lower than the pOTTIS
[36]. However, this is unlikely to influence the relative
benefit of moxidectin compared to ivermectin regarding
reduced programme duration, as seen by the consistency
of the relative benefit over the different values of the pOT-
TIS applied in the sensitivity analysis (Figures 2 and 3).
In the context of integrated NTD control, there is
renewed interest in the broader antiparasitic properties
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onchocerciasis and other helminthiases, particularly
lymphatic filariasis and soil-transmitted helminthiasis
[16]. Scabies is another infection treatable with ivermectin
for which evaluation of moxidectin has been proposed
[37]. It will thus be important to establish whether moxi-
dectin has similar effects to those of ivermectin on a range
of human parasites—as data from veterinary use suggest
[16] —and, therefore, whether it has strong potential for
integrated control of helminth and other infections. This
is particularly important now that APOC may become a
new regional entity, the Programme for the Elimination of
Neglected Diseases in Africa (PENDA), with a wider
mandate to tackle all the five preventive chemotherapy
diseases, including lymphatic filariasis and onchocerciasis
elimination [38,39].
Conclusions
Annual CDTM could result in achieving the proposed
thresholds for stopping treatment in Africa within time-
frames comparable to those achievable with biannual
CDTI, but at a substantially lower cost to countries (pro-
vided moxidectin is donated). Moreover, the effectiveness
of annual CDTM is essentially impervious to seasonal
peaks in transmission, whereas suboptimal timing of
annual CDTI can significantly reduce its effectiveness.
Moxidectin, therefore, represents a potentially superior
alternative drug for onchocerciasis control and elimination.
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